Logo for LaunchBio Program: NextGen VC ForumLogo for LaunchBio Program: NextGen VC Forum

The pemiere Event for Venture Capital Associates to Expand their Skills and Expertise

Cure, 345 Park Avenue South, NYC

NextGen VC Forum NYC

Mid-level VC associates expanding skills and expertise and growing networks


Curated by Wilson Sonsini’s Michael Hostetler and Dan Koeppen, LaunchBio’s NextGen VC Forum is the premiere event for venture capital associates to expand their skills and expertise while growing their network. The half-day forum includes a networking breakfast, three one-hour sessions and lunch. Attendance at NextGen VC Forum is by invitation only.

Join Michael, Dan, and LaunchBio for a half-day program VC associates won’t want to miss!



9:00 am – Arrival at Cure /Check-in/light breakfast and networking

9:45 am – Welcome and introduction by hosts Dan Koeppen & Mike Hostetler

10:00 am – On Your Terms – Negotiating Term Sheets Part 1 with Marty Waters & Salil Gandhi

11:00 am – Understanding and Leveraging IP & Licensing Diligence in Investment Decisions with Clark Lin & Seth Flaum

12:00 pm – Lunch/Networking

1:00 pm – Board Governance with Amy Simmerman

2:00 pm – Networking and refreshments with Cure. members

3:00 pm – Close


PANEL 1 • On Your Terms – Negotiating Term Sheets Part 1

Life science venture capitalists must be familiar with the key terms and provisions in term sheets when negotiating with startups. They should also have a solid understanding of the negotiation process and be able to effectively negotiate and protect their interests while also ensuring that the startup is able to successfully reach its goals. In this session, participants will gain clarity and depth in understanding term sheets and the negotiation process.

PANEL 2 • Assessing the Risk – Leveraging IP Diligence

To make informed investment decisions and assess the risks and opportunities effectively, life science venture capitalists must understand the importance of conducting thorough IP diligence when evaluating potential investment opportunities in this space. We’ll cover IP due diligence, patents, freedom-to-operate, IP licensing and IP litigation so venture capitalists can confidently know their assets.

PANEL 3 • All Aboard! – Understanding Board Governance

To represent their interests, protect their investments, and ensure the company is being managed effectively, life science venture capitalists should be well versed in board governance. In this panel, we’ll dive into representation, oversight, alignment, board dynamics, compliance and more. Life science venture capitalists will be able to immediately apply new knowledge and skills for better governance, ultimately maximizing their investments


  • Mike Hostetler Wilson Sonsini

    Michael Hostetler, PhD, partner, Wilson Sonsini

    Mike’s expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology products in all stages of development, from proof of concept to regulatory approval to product launch. Mike has also counseled well over 100 venture capital firms in their investments in biotech and pharmaceutical companies.

  • Dan Koeppen

    Dan Koeppen, Partner, Wilson Sonsini

    Dan is a “company-building” corporate attorney that has extensive experience representing public and private life science companies in a wide range of sectors, including biotechnology, consumer products, medical device, pharmaceutical, and therapeutics. He specializes in corporate governance, mergers and acquisitions, public offerings, PIPE financings, securities matters, strategic transactions and venture capital financings, and guides companies through all stages of their growth.

  • Marty Waters

    Martin Waters, Partner Corporate, Wilson Sonsini

    Martin (Marty) Waters is a corporate and securities partner in the San Diego office. He is a founding partner of the firm’s San Diego office and Southern California corporate practice. He was a partner in the Palo Alto office until opening the San Diego office in 2004. He has served as a member of the firm’s board of directors. Marty is a proven company builder with more than 25 years of experience providing corporate and securities counsel to high growth private and public companies.

  • Salil Gandhi

    Salil Gandhi Partner Corporate, Wilson Sonsini

    Salil Gandhi is a partner in the New York office of Wilson Sonsini Goodrich & Rosati and a co-leader of the firm’s emerging companies practice. Salil focuses on corporate and securities law and specializes in the representation of emerging growth companies throughout their lifecycles, particularly in the life sciences and technology sectors. He also counsels venture capital funds and other private equity funds on structuring and executing investment transactions ranging from angel to control investments, as well as portfolio dispositions.

  • Clark Lin

    Clark Y. Lin, PhD, Partner Patents and Innovations, Wilson Sonsini

    Dr. Clark Y. Lin is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office. He practices intellectual property law, with an emphasis on patent prosecution, general intellectual property counseling, and intellectual property litigation. Clark focuses on developing, managing, and leveraging global patent portfolios for life science companies. His patent expertise includes the fields of immunotherapies, specialty pharmaceuticals, antibody and protein therapeutics, gene therapies, cell therapies, CRISPR gene editing and RNA therapies. With experience in over 20 issuer-side public offerings, Clark also assists life science companies through the IPO process from an intellectual property perspective.

  • Seth Flaum

    Seth Flaum Partner Technology Transactions, Wilson Sonsini

    Seth is a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters. Prior to joining the firm, Seth was the executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan, where he trained and managed a team of lawyers and business
    professionals responsible for implementing the company’s global business development transactions.

  • Amy Simmerman

    Amy Simmerman, Partner, Wilson Sonsini

    Amy is a leader of the firm’s Delaware office and governance practice, and she serves on the firm’s board of directors. Her practice focuses on providing advice on all aspects of Delaware corporate law and related corporate governance issues, including fiduciary duties, mergers and acquisitions, stockholder activism, corporate formation, stock issuances, preferred stock investments, and various statutory matters. Amy regularly represents special committees of boards of directors in mergers and acquisitions, internal investigations, and other matters, and she provides corporate advice in the context of governance litigation.